BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 1326622)

  • 1. Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
    Comer SD; Burke TF; Lewis JW; Woods JH
    J Pharmacol Exp Ther; 1992 Sep; 262(3):1051-6. PubMed ID: 1326622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice.
    Burke TF; Woods JH; Lewis JW; Medzihradsky F
    J Pharmacol Exp Ther; 1994 Nov; 271(2):715-21. PubMed ID: 7965787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
    Barrett AC; Smith ES; Picker MJ
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
    Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
    Zernig G; Butelman ER; Lewis JW; Walker EA; Woods JH
    J Pharmacol Exp Ther; 1994 Apr; 269(1):57-65. PubMed ID: 8169852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.
    Adams JU; Paronis CA; Holtzman SG
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1027-32. PubMed ID: 2175793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.
    Pitts RC; Allen RM; Walker EA; Dykstra LA
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1197-206. PubMed ID: 9618423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methoclocinnamox: agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys.
    Butelman ER; Lewis JW; Woods JH
    J Pharmacol Exp Ther; 1996 Nov; 279(2):934-8. PubMed ID: 8930202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
    McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.
    Gistrak MA; Paul D; Hahn EF; Pasternak GW
    J Pharmacol Exp Ther; 1989 Nov; 251(2):469-76. PubMed ID: 2553921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
    Kögel B; Christoph T; Strassburger W; Friderichs E
    Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: evidence for multiple diverse hyperalgesic systems.
    Juni A; Klein G; Kest B
    Brain Res; 2006 Jan; 1070(1):35-44. PubMed ID: 16409995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice.
    Takemori AE; Portoghese PS
    J Pharmacol Exp Ther; 1987 Oct; 243(1):91-4. PubMed ID: 2822908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats.
    Walker EA; Makhay MM; House JD; Young AM
    J Pharmacol Exp Ther; 1994 Nov; 271(2):959-68. PubMed ID: 7965818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine.
    Walker EA; Young AM
    J Pharmacol Exp Ther; 2002 Jul; 302(1):101-10. PubMed ID: 12065706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone antagonizes the analgesic and immunosuppressive effects of morphine in mice.
    Carr DJ; Gerak LR; France CP
    J Pharmacol Exp Ther; 1994 May; 269(2):693-8. PubMed ID: 8182537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
    Mjanger E; Yaksh TL
    J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
    Sterious SN; Walker EA
    J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects.
    France CP; Winger G; Medzihradsky F; Seggel MR; Rice KC; Woods JH
    J Pharmacol Exp Ther; 1991 Aug; 258(2):502-10. PubMed ID: 1650830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.